title: Why these biotechs are as hot as net stocks. Wall Street's betting big on a genetic technology that burned it badly before. Monoclonal antibodies still don't cure cancer--but this time they may actually pay off.
authors.forename: B
authors.initials: B
authors.lastname: McLean
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics*; D001709:Biotechnology / Q000191:economics*; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D020407:Internet / Q000191:economics*; D007449:Investments / Q000191:economics*; D009369:Neoplasms / Q000628:therapy; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal